Eylward Susan 4

What Happened

• Susan Eylward, General Counsel and Corporate Secretary of Imunon, was granted 920 shares on 2026-07-02 at a per-share value of $1.91 (total $1,757) and sold 920 shares on 2026-07-06 in an open-market transaction at $1.88 per share (total $1,730). The grant was reported as an acquisition (award) and the later transaction as a sale (disposition).

Key Details

• Transaction dates and prices:
  • 2026-07-02: Award/acquisition — 920 shares @ $1.91 each = $1,757
  • 2026-07-06: Open-market sale — 920 shares @ $1.88 each = $1,730
• Shares owned after the transactions: not specified in the provided filing summary.
• Footnote: The 920 shares were "stock granted in lieu of cash for portion of base salary" (per filing footnote).
• Filing: Form 4 filed 2026-07-07 reporting the Jul 2 and Jul 6 transactions; Form 4s are generally due within two business days of a transaction — review the full filing for any timeliness notes.

Context

• The initial transaction was an award (compensation in stock), not a purchase with cash — awards are common for payroll or compensation and don’t necessarily signal buying conviction. The subsequent open-market sale appears to dispose of the awarded shares shortly after receipt. This pattern (award then sell) is often a routine liquidity action rather than an indicator of company outlook.